Table 6.
The clinical characteristics of symptomatic and asymptomatic cases.
| Clinical Characteristics | Symptomatic Cases (n = 17) | Asymptomatic Cases (n = 24) |
|---|---|---|
| Symptoms | ||
| Fever | 41.2% (7) | 0 |
| Headache | 17.6% (3) | 0 |
| Cough | 17.6% (3) | 0 |
| Pharyngalgia | 5.9% (1) | 0 |
| Runny Nose | 11.8% (2) | 0 |
| Digestive tract symptoms | 17.6% (3) | 0 |
| Time to diagnosis (days) | 6.1 ± 8.1 | 2.0 ± 0.6 |
| Nucleic acid testing | ||
| Throat swab | 82.4% (14) | 62.5% (15) |
| Nose swab | 47.1% (8) | 50.0% (12) |
| Anal swab | 29.4% (5) | 37.5% (9) |
| Coronavirus antibodies | ||
| IgG | 71.4% (5/7) | 84.2% (16/19) |
| IgM | 14.3% (1/7) | 21.1%(4/19) |
| complications | ||
| Hypertension | 17.6% (3) | 4.2% (1) |
| Cardiovascular disease | 17.6% (3) | 4.2% (1) |
| Respiratory disease | 5.9% (1) | 0 |
| Cancer | 0 | 0 |
| Diabetes | 0 | 0 |
| Kidney disease | 5.9% (1) | 0 |
| The history of blood transfusion | 11.8% (2) | 0 |
| Allergic history | 5.9% (1) | 8.3% (2) |
| Disease classification | ||
| Asymptomatic infection | 0% (0) | 100% (24) |
| Mild | 88.2% (15) | 0% (0) |
| Severe | 11.8% (2) | 0% (0) |
| Lung CT | ||
| Inflammation | 70.6% (12) | 20.8% (5) |
| Pneumatocele | 11.8% (2) | 4.2% (1) |
| Other (nodule, cord, pleural thickening, pleural thickening) | 35.3% (6) | 12.5% (3) |
| Length of stay | ||
| Mean ± S.D. | 21.9 ± 8.4 | 16.8 ± 5.2 |
| Treatment | ||
| Antibiotic | 0 | 12.5% (3) |
| Antiviral | ||
| Arbidol | 41.7% (10) | 95.8% (23) |
| Traditional Chinese medicine | 76.5% (13) | 95.8% (23) |
| Lopinavir/ Ritonavir | 35.3% (6) | 0 |
| Human Immunoglobulin (I.V) | 0 | 0 |
| Glucocorticoid | 0 | 0 |
| Hydroxychloroquine | 23.5% (4) | 4.2% (1) |
| IFN-α (INH) | 94.1% (16) | 100% (24) |
| Oxygen intracavitary | ||
| low-flow nasal oxygen | 23.5% (4) | 0 |
| Noninvasive mechanical ventilation | 0 | 0 |
| Invasive mechanical ventilation | 0 | 0 |
| Clinical outcome | ||
| Death | 0 | 0 |
| Re-positive | 23.5% (4) | 20.8% (5) |